Reach Us +44-1474-556909
Development Of Extremely Excellent Anti-HIV Active EFdA, Focused On The Design | 79322
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

33rd World Congress on Pharmacology

Barcelona, Spain

7th European Biopharma Congress

Prague, Czech Republic
Share This Page

Development of extremely excellent anti-HIV active EFdA, focused on the design

Joint Event on 4th European Biopharma Congress & 6th International Conference and Exhibition on Pharmacology and Ethnopharmacology

Hiroshi Ohrui

Yokohama University of Pharmacy, Japan

Keynote: Clin Pharmacol Biopharm

DOI: 10.4172/2167-065X-C1-024

4’-C-Ethynl-2’-fluoro-2-deoxyadenosine (EFdA) has attracted much attention due to its extremely excellent anti-HIV properties (1. prevent the emergence of resistant HIV mutants 2. over 400 times more active than AZT and several orders of magnitude more active than the other clinical reverse-transcriptase inhibitor 2’, 3’-dideoxynucleoside drugs 3. very low toxic 4. long acting 5. could be used for prophylaxis, and so on). EFdA is now under clinical investigation as MK-8591 by Merck & Co. In my talk, the development of EFdA, especially the design of it will be presented and discussed. For the design of the modified nucleoside which could solve the problems (1. emergence of drug-resistant HIV-mutants. 2. adverse effects by drugs. 3. necessary to take plenty number of drugs) that the clinical drugs have, I have proposed the following working hypotheses to solve the problems. They are: (1) the way to prevent the emergence of resistant HIV mutants, (2) the way to decrease the toxicity of modified nucleosides, (3) the way to provide the nucleoside with the stability to both enzymatic and acidic hydrolysis of nucleobase. 4’-C-substituted-2’-deoxynucleoside was designed to meet the hypotheses (1), (3) and the 2-site-modification was conducted to meet the hypothesis (2). The details of the hypotheses and the reason of the 4’-C-substitution will be discussed. To prevent the deamination of adenine base, fluorine atom was introduced at the 2-position of adenine base. Finally, EFdA which is modified at the two positions of the physiologic 2’-deoxyadenosine and has extremely excellent anti-HIV properties been successfully developed.

Hiroshi Ohrui received his PhD degree (1971) from The University of Tokyo. He joined RIKEN during 1966 and moved to Tokyo University in 1981 and moved to Yokohama University of Pharmacy in 2006. He worked for Dr. J J Fox at Sloan- Kettering Institute for Cancer Research during 1972-1973 and Dr. J G Moffatt at Syntex Research during 1973-1974. He received several awards including Inoue Prize for Science (2001), Japan Prize for Agricultural Sciences (2004), The Japan Society for Analytical Chemistry Award (2004), and Japan Academy Prize (2010). His research interests cover organic synthesis, chemical biology and chiral discrimination.